---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021212"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:41:36.859164+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q1 net loss $27.5M; cash $192.7M funds operations into 2025

## Summary
- Cash and equivalents $192.7M as of March 31, 2023, down from $215.5M at Dec 31, 2022.
- Net loss $27.5M vs $24.3M in Q1 2022; R&D expense rose to $21.7M from $16.9M.
- Phase 2 potentially registrational BA3011 UPS study enrolling; LMS cohort readout expected 2H23.
- FDA meeting request for BA3011 NSCLC Phase 2 part 2 on track for 1H23; initiation in 2H23.
- BA3021 NSCLC interim readout and BA3071 Phase 1 data readout both on track for 2H23.

## SEC filing metadata
- accession: 0000950170-23-021212
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/0000950170-23-021212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/bcab-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021212
- JSON: https://secwatch.observer/filing/0000950170-23-021212.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.